Steven E. Benner, MD, Senior Vice President and Global Therapeutic Head for Oncology at Astellas Oncology discusses a phase 1 study of enfortumab vedotin for metastatic urothelial cancer, which was presented by Daniel Peter Petrylak, MD of Yale Cancer Center at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract 106: A phase 1 study of enfortumab vedotin (ASG-22CE; ASG-22ME): Updated analysis of patients with metastatic urothelial cancer
Advertisement